ストックスクリーナーアプリを入手
45.86
2.00%
0.90
アフターアワーズ：
46.15
0.29
+0.63%
前日終値:
$44.96
開ける：
$45.15
24時間の取引高:
2.53M
Relative Volume:
0.93
時価総額：
$11.91B
収益：
$2.32B
当期純損益:
$782.57M
株価収益率:
16.47
EPS:
2.7838
ネットキャッシュフロー:
$875.84M
1週間 パフォーマンス:
+4.25%
1か月 パフォーマンス:
+11.20%
6か月 パフォーマンス:
+16.07%
1年 パフォーマンス:
+28.32%
1日の値動き範囲:
$45.01
$46.03
1週間の範囲:
$43.75
$46.03
52週間の値動き範囲:
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
45.86 | 11.50B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Working capital per share of Exelixis, Inc. – BX:EX9 - TradingView — Track All Markets
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference - Yahoo
EXELAnnual Report (10-k) - ADVFN
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - ADVFN
Neuroendocrine Tumor Treatment Market size to cross $5.12 - openPR.com
How (EXEL) Movements Inform Risk Allocation Models - Stock Traders Daily
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)? - Sahm
Stock Report: Can Exelixis Inc sustain its profitability2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Nisa Investment Advisors LLC Has $6.16 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Tema Etfs LLC Grows Position in Exelixis, Inc. $EXEL - MarketBeat
Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Moving Averages: Is Exelixis Inc a play on infrastructure spendingGlobal Markets & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis: A Strong Contender in the Cancer Drug Market - The Globe and Mail
Kidney Cancer Drugs Market to Grow by $2 Billion During - GlobeNewswire
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Trading Systems Reacting to (EXEL) Volatility - Stock Traders Daily
Exelixis, Inc. $EXEL Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
RBC Capital lowers Exelixis (EXEL) price target to $43 - MSN
MIC:EXEL-RM OCF Yield %: 8.20 — 52% Above Median - GuruFocus
Exelixis, Inc. $EXEL Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 - Insider Monkey
15 Set-It-and-Forget-It Stocks to Buy in 2026 - Insider Monkey
Exelixis (MIC:EXEL-RM) NonCurrent Deferred Revenue : ₽0.00 Mil (As of Dec. 2025) - gurufocus.com
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
EXEL Financials: Income Statement, Balance Sheet & Cash Flow | Exelixis Inc - Stock Titan
Vanguard disaggregates holdings; Exelixis (NASDAQ: EXEL) shows 0 shares - Stock Titan
Exelixis (NASDAQ:EXEL) Raised to Strong-Buy at Truist Financial - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by Nordea Investment Management AB - MarketBeat
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
EXEL Stock Price, Quote & Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
大文字化:
|
ボリューム (24 時間):